Details:
Patent covers the chemical composition of SmartCelle polymers, their method of manufacture and their ability to form 20nm-30nm stable drug-loaded dynamic micelles in aqueous solution. SmartCelle formulations comprising a number of anti-inflammatory drugs are presented.
Lead Product(s): TA-A001
Therapeutic Area: Ophthalmology Product Name: TA-A001
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Combination of CBN and elevated pressure, within the same time period, resulted in a high level of cell survival in a dose dependent fashion. CBN was superior to both CBD and THC under identical testing conditions.
Lead Product(s): Cannabinol
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
With INM-088, an eye drop formulation of CBN, the Company is exploring the treatment for glaucoma, either as a prospective stand-alone or an adjunct therapy, and in other ocular diseases.
Lead Product(s): Cannabinol
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020